NCT01549951View on ClinicalTrials.gov

Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Prostate Cancer
Interventions
DRUG

Orteronel+Prednisone

Orteronel 400-mg plus prednisone 5-mg will be administered BID orally continuously throughout the treatment cycle of the study.

Trial Locations (1)

85258

Pinnacle Oncology, Scottsdale

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY